Watch Ticker

Veracyte, Inc.

Go to Veracyte, Inc. Website

$25.10

0.78 (3.21%)

Live

Previous Close

$25.01

Day Range

$24.15 - $25.075

Previous Day Range

$23.35 - $24.52

Market Cap

$1.9 billion USD

Day Vol.

1.6 million

Previous Day Vol.

1.2 million

Currency

USD

Primary Exchange

Nasdaq

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate)...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Researchandmarkets.Com - Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

Related tickers: ADPT, AMGN, AZN, TECH, BIO, BIO.B, BMY, CELGr, EXAS, RHHBY, ILMN, GH, GILD, LH, MDXH, MYGN, NTRA, NEO, OPK, DGX, SSMXY, VCYT.

Read Full Article

Vandana Singh - Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte is considering selling or shutting down its French subsidiary, which generates $4 million in revenue but incurs $7 million in fixed costs, leading to a $5 million loss. An analyst believes this could be a long-term positive for the company.

Related tickers: VCYT.

Read Full Article

Trending Tickers

Please sign in to view